Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $17.00 ...

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bausch + Lomb Co. (NYSE:BLCO – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday after ...

The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...

A chat with my childhood sporting hero to discuss a fundraising dinner took us back to the golden days of World Series ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.

J.P. Morgan analysts said it was too early to discuss the financial impact of the recall, but estimated that $70 million to ...

A new breed of auction sleeper hunter—and my own doom-scrolling about the geopolitical realities of 2025—have led me to ...